Table 2. Effect of treatment on PET/CT parameters.
| Change from baseline to day 56 | Difference from control at day 56 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted for differences at baseline | ||||||||
| Mean | 95% CI | P | Mean | 95% CI | P | Mean | 95% CI | P | |
| Log peak SUVbw | |||||||||
| Control | -0.089 | -0.131; -0.042 | <0.001 | 0 | - | - | 0 | - | - |
| CC-11050 | -0.087 | -0.152; -0.022 | 0.010 | -0.010 | -0.098; 0.078 | 0.824 | -0.006 | -0.085; 0.073 | 0.888 |
| Everolimus | -0.178 | -0.253; -0.092 | <0.001 | -0.140 | -0.229; -0.050 | 0.002 | -0.117 | -0.197; -0.037 | 0.005 |
| Auranofin | -0.101 | -0.169; -0.038 | 0.003 | 0.018 | -0.069; 0.106 | 0.684 | 0.001 | -0.078; 0.079 | 0.986 |
| Ergocalciferol | -0.133 | -0.203; -0.076 | <0.001 | -0.014 | -0.102; 0.074 | 0.706 | -0.029 | -0.108; 0.050 | 0.466 |
| Log max SUVbw | |||||||||
| Control | -0.060 | -0.101; -0.019 | 0.006 | 0 | - | - | 0 | - | - |
| CC-11050 | -0.070 | -0.130; -0.009 | 0.025 | -0.014 | -0.085; 0.056 | 0.685 | -0.013 | -0.079; 0.054 | 0.704 |
| Everolimus | -0.134 | -0.201; -0.067 | <0.001 | -0.111 | -0.182; -0.040 | 0.002 | -0.100 | -0.168; -0.033 | 0.004 |
| Auranofin | -0.077 | -0.139; -0.015 | 0.016 | 0.002 | -0.068; 0.072 | 0.958 | -0.007 | -0.073; 0.059 | 0.844 |
| Ergocalciferol | -0.133 | -0.190; -0.075 | <0.001 | -0.039 | -0.109; 0.031 | 0.274 | -0.050 | -0.117; 0.016 | 0.137 |
| Log total SUVbw*ml | |||||||||
| Control | -0.154 | -0.190; -0.119 | <0.001 | 0 | - | - | 0 | - | - |
| CC-11050 | -0.144 | -0.187; -0.100 | <0.001 | -0.045 | -0.130; 0.040 | 0.296 | -0.006 | -0.061; 0.050 | 0.838 |
| Everolimus | -0.159 | -0.201; -0.117 | <0.001 | -0.112 | -0.198; -0.025 | 0.012 | -0.038 | -0.095; 0.019 | 0.184 |
| Auranofin | -0.158 | -0.203; -0.112 | <0.001 | 0.004 | -0.081; 0.088 | 0.934 | -0.003 | -0.058; 0.053 | 0.928 |
| Ergocalciferol | -0.180 | -0.234; -0.125 | <0.001 | -0.023 | -0.108; 0.062 | 0.598 | -0.018 | -0.074; 0.037 | 0.519 |
| Log total mHU*ml | |||||||||
| Control | -0.050 | -0.065; -0.036 | <0.001 | 0 | - | - | 0 | - | - |
| CC-11050 | -0.040 | -0.057; -0.023 | <0.001 | -0.025 | -0.069; 0.018 | 0.252 | 0.005 | -0.018; 0.027 | 0.692 |
| Everolimus | -0.059 | -0.078; -0.041 | <0.001 | -0.049 | -0.093; -0.005 | 0.030 | -0.016 | -0.039; 0.007 | 0.160 |
| Auranofin | -0.045 | -0.060; -0.031 | <0.001 | 0.015 | -0.028; 0.058 | 0.501 | 0.006 | -0.016; 0.028 | 0.610 |
| Ergocalciferol | -0.064 | -0.084; -0.044 | <0.001 | -0.015 | -0.058; 0.029 | 0.512 | -0.011 | -0.034; 0.011 | 0.328 |
In the left panel, differences were determined by paired t test. In the right panel, differences were determined by ANCOVA, before and after adjustment based on differences from control at baseline in that parameter (eg, analysis of log peak SUVbw was adjusted for baseline differences in log peak SUVbw). SUVbw = standardized uptake value adjusted for body weight. CI = confidence interval; mHU = modified Hounsfield units.